Supernus Pharmaceuticals, Inc. (SUPN)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.52B
Last updated: Nov 17, 2026 at 4:33 PM ET
Supernus Pharmaceuticals, Inc. (SUPN) Statistics
Supernus Pharmaceuticals (SUPN) has a market cap of $1.52B and an enterprise value of $1.34B. Its trailing P/E of 12.8x is below its 10-year median of 54.9x. Revenue grew 24.85% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 11.81% below the market cap, as cash exceeds debt.
| Market Cap | $1.52B |
|---|---|
| Enterprise Value | $1.34B |
| Latest price (Nov 17, 2026) | $29.04 |
Key Dates
The next earnings report is expected on Feb 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 2.0x and 1.6x. Its year-end P/E ranged from 12.6x to 158.1x from 2016 to 2025.
| P/E Ratio | 12.8x |
|---|---|
| Forward P/E | 12.8x |
| P/S Ratio | 2.0x |
| Forward P/S | 1.1x |
| P/B Ratio | 1.6x |
| P/TBV Ratio | 3.8x |
| P/FCF Ratio | 89.8x |
| P/OCF Ratio | 76.5x |
| PEG Ratio | 0.6 |
Enterprise Valuation
Counting debt and cash, the company is valued at 80.2x free cash flow.
| EV / Sales | 1.6x |
|---|---|
| EV / FCF | 80.2x |
Price Statistics
The stock is down 35.47% over 52 weeks and trades 5.45% above its 50-day average.
| Beta (1Y) | 0.54 |
|---|---|
| 52-Week Change | -35.47% |
| 1-Month Change | +10.50% |
| 3-Month Change | -4.13% |
| 6-Month Change | -39.02% |
| 5-Year Change | -76.30% |
| 10-Year Change | -64.27% |
| Total Return (1Y) | -17.40% |
| Total Return (3Y CAGR) | +1.92% |
| Total Return (5Y CAGR) | -2.44% |
| Return vs SPY (1Y) | -46.88% |
| Max Drawdown (1Y) | -55.29% |
| Max Drawdown (3Y) | -55.83% |
| Sharpe Ratio (1Y) | -1.01 |
| Correlation with SPY (1Y) | 0.17 |
| 50-Day Average | $27.54 |
| 200-Day Average | $38.50 |
| 52-Week Range | $21.48 to $33.22 |
| RSI (14 Days) | 57.6 |
| Average Volume (20 Days) | 3.83M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.08x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 2.08x |
|---|---|
| Quick Ratio | 1.84x |
| Debt / Equity | 0.00x |
| Interest Coverage | 2.15x |
Returns and Efficiency
Return on equity is -10.66% over the last 12 months, against a 5-year average of 3.41%.
| Return on Equity (ROE) | -10.66% |
|---|---|
| Return on Assets (ROA) | -7.69% |
| Return on Capital Employed (ROCE) | -11.42% |
| ROE (5Y Average) | 3.41% |
| ROA (5Y Average) | 1.92% |
| ROIC (5Y Average) | 0.39% |
| Asset Turnover | 0.59x |
| Inventory Turnover | 1.16x |
| Receivables Turnover | 4.22x |
| Cash Conversion Cycle | 15 days |
Scores
SUPN has an Altman Z-Score of 3.61, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.61 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $830.44M over the last 12 months.
| Revenue | $830.44M |
|---|---|
| Revenue Growth (YoY) | +24.85% |
| Gross Profit | $731.41M |
| Operating Income | -$130.46M |
| Pretax Income | -$123.47M |
| Net Income | -$109.89M |
| EBITDA | -$22.72M |
| EBIT | -$123.47M |
| Reported EPS (TTM) | $2.26 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
Shareholder equity funds 72.03% of the $1.43B in total assets.
| Cash and Equivalents | $179.95M |
|---|---|
| Total Debt | $0 |
| Net Cash | $179.95M |
| Net Cash Per Share | $3.10 |
| Working Capital | $376.12M |
| Shareholder Equity | $1.03B |
| Book Value Per Share | $17.76 |
| Tangible Book Value | $442.34M |
| Tangible Book Per Share | $7.62 |
| Total Assets | $1.43B |
| Total Liabilities | $396.88M |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $1.12M of capital spending, operating cash flow left $18.79M of free cash flow.
| Operating Cash Flow | $19.91M |
|---|---|
| Capital Expenditures | $1.12M |
| Free Cash Flow | $18.79M |
| FCF Per Share | $0.32 |
| Depreciation and Amortization | $103.65M |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is -15.71%, against a 5-year average of 4.91%.
| Gross Margin | 88.07% |
|---|---|
| Operating Margin | -15.71% |
| Pretax Margin | -14.87% |
| Net Margin | -13.23% |
| EBITDA Margin | -2.74% |
| EBIT Margin | -14.87% |
| FCF Margin | 2.26% |
| Gross Margin (5Y Average) | 87.61% |
| Operating Margin (5Y Average) | 4.91% |
| Net Margin (5Y Average) | 4.87% |
Growth
Revenue grew 2.52% a year over 3 years, and EPS 23.20% a year.
| Revenue Growth (3Y CAGR) | +2.52% |
|---|---|
| Revenue Growth (5Y CAGR) | +6.68% |
| EPS Growth (3Y CAGR) | +23.20% |
| EPS Growth (5Y CAGR) | +3.79% |
| FCF Growth (3Y CAGR) | -26.62% |
| FCF Growth (5Y CAGR) | -19.34% |
| Book Value Per Share Growth (2Y CAGR) | +5.18% |
| Tangible Book Per Share Growth (2Y CAGR) | +31.30% |
Dividends and Yields
SUPN does not pay a dividend. Its free cash flow yield is 1.11%.
| Earnings Yield | 7.81% |
|---|---|
| FCF Yield | 1.11% |
| Buyback Yield | -2.97% |
| Shareholder Yield | -2.97% |
Stock Splits
The last split was a 1-for-5 reverse split on Oct 11, 2022.
| Last Split Date | Oct 11, 2022 |
|---|---|
| Split Type | Reverse split |
| Split Ratio | 1:5 |
Peer Position
Against 11 similar companies, SUPN has the 5th highest P/E.
P/E RatioPeer median 10.7x
P/S RatioPeer median 2.0x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.45%
| P/E Ratio | 12.8x vs 10.7x median |
|---|---|
| P/S Ratio | 2.0x vs 2.0x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +24.85% vs +10.45% median |
Analyst Forecast
Consensus estimates put revenue growth at 39.52% and EPS growth at 25.93% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +39.52% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +25.93% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About SUPN
What is SUPN's market cap?
Supernus Pharmaceuticals has a market cap of $1.52B. Its enterprise value, which adds debt and subtracts cash, is $1.34B.
What is SUPN's P/E ratio?
Supernus Pharmaceuticals has a trailing P/E ratio of 12.8x and a forward P/E of 12.8x.
How many shares of SUPN are outstanding?
Supernus Pharmaceuticals has 58.07M shares outstanding. The count is up 3.65% from a year earlier.
Does SUPN pay a dividend?
No. Supernus Pharmaceuticals does not pay a dividend.
How much debt does SUPN have?
Supernus Pharmaceuticals has $0 of total debt and $179.95M of cash and equivalents, a net cash position of $179.95M.
SUPN pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors